NEW YORK - MiNK Therapeutics, Inc. (NASDAQ: INKT), a biopharmaceutical company focused on developing cell therapies for cancer and immune diseases, announced it has regained compliance with Nasdaq's market value of listed securities requirement. The company received confirmation from Nasdaq on July 23, 2024, that it had satisfied the necessary conditions for continued listing on the Nasdaq Capital Market.
The Nasdaq Listing Rule 5550(b)(2) specifies the market value requirements that companies must meet to maintain their presence on the exchange. MiNK Therapeutics' compliance closes the matter regarding its listing status.
MiNK Therapeutics specializes in the development of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies. The company's pipeline includes both native and engineered iNKT cell programs, with a focus on scalable manufacturing processes for widespread availability. Headquartered in New York, NY, MiNK Therapeutics aims to advance treatments for a range of serious medical conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.